Phage composition for treating pathogenic escherichia coli infection as well as preparation method and application thereof

By combining multiple phages, the problems of resistance mutations and narrow host spectrum of pathogenic E. coli are solved, effective inhibition and clearance of E. coli are achieved, and a new bactericidal method is provided to avoid the use of antibiotics. The toxic side effects of traditional therapy.

CN118909976AActive Publication Date: 2024-11-08QINGHAI UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411303456.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-08
Estimated Expiration
2044-09-18

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the problem of resistance mutations in pathogenic E. coli and the narrow range of phage host spectrum, and the use of traditional antibiotics has led to increased drug resistance, and a new bactericidal method is needed to replace antibiotics.

Method used

A variety of different phages (such as ECP2301, ECP2304, ECP2307) are mixed and prepared into a phage composition. By inhibiting E. coli infection in vitro and using it as a food pathogenic E. coli scavenger, the synergistic effect of phages is used to improve the inhibitory effect.

Benefits of technology

The stable biological characteristics and lytic activity of pathogenic E. coli are achieved, the inhibitory ability of anti-bacterial bacteria is enhanced, the prevention and treatment effect is improved, and the toxic side effects of traditional small molecule therapy are avoided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909976A_ABST
    Figure CN118909976A_ABST
Patent Text Reader

Abstract

The invention provides a bacteriophage composition for treating pathogenic escherichia coli infection as well as a preparation method and application thereof, and belongs to the technical field of food safety. The invention provides a bacteriophage which has a splitting effect on pathogenic escherichia coli, and the bacteriophage comprises ECP2301, ECP2304 and ECP2307 and has an important bacteriostatic effect on host bacteria of the pathogenic escherichia coli. The three bacteriophages in the bacteriophage composition provided by the invention respectively have relatively strong lysis performance on escherichia coli MQ220627, MQ1 and YS220605, and the three bacteriophages are mixed to generate a synergistic effect, so that the bacteriophage composition has a more efficient inhibition effect compared with a single bacteriophage, can be used as a pathogenic escherichia coli scavenger for milk and meat, and has a good effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of food safety, and in particular relates to a bacteriophage composition for treating pathogenic Escherichia coli infection, a preparation method and an application thereof. Background Art

[0002] Escherichia coli is the most common commensal bacteria in the gastrointestinal tract of humans and animals, and is also the most important pathogen. When the external environment affects the body, there are more and more cases of economic animals suffering from diarrhea, meningitis and other diseases due to pathogenic Escherichia coli in farms, which has brought huge losses to the breeding industry. At present, the main prevention and control measure for enteropathogenic Escherichia coli is the use of antibiotics, but due to the large-scale use of antibiotics, the problem of drug resistance is very prominent. The demand for alternative antibiotics is increasing, so there is an urgent need to develop a new sterilization method to replace antibiotics.

[0003] Phage therapy uses bacterial viruses, or phages, to target and destroy bacteria at different sites of infection. Recent advances in biotechnology have enabled the rapid expansion of existing phage libraries, resulting in the generation of potent and specific phages that can target and destroy bacteria of interest. Pathogenic E. coli can cause diarrhea in a variety of animals. In addition, some pathogenic E. coli strains are antibiotic resistant, making it difficult to treat chronic E. coli-associated infections. Phage therapeutic approaches that can bypass traditional antibiotic resistance mechanisms, avoid the toxic side effects of traditional small molecule therapies, and are effective against biofilms are particularly attractive.

[0004] Bacteriophages are a type of virus that specifically infects target bacteria and replicates itself. Virulent phages have the advantages of host bacterial specificity, self-replication, strong lysis ability, no toxicity to animals and plants, environmental friendliness and easy production. Therefore, phage therapy has great potential in the biological control of bacterial diseases. Most phages have a narrow host spectrum and can only infect one or a few strains; therefore, the use of a single phage preparation will limit the control effect and easily lead to the emergence of resistant bacteria. Summary of the invention

[0005] The purpose of the present invention is to provide a phage composition for treating pathogenic Escherichia coli infection, a preparation method and an application thereof. A phage composition prepared by mixing a plurality of different phages has more stable biological properties and lytic activity, and can also effectively solve the problems of bacterial resistance mutation and narrow phage host spectrum.

[0006] The present invention provides a bacteriophage having a lytic effect on pathogenic Escherichia coli, wherein the bacteriophage comprises at least one of the following: ECP2301, ECP2304 and ECP2307;

[0007] Among them, the preservation number of ECP2301 is CCTCC NO:M 20241608, the preservation number of ECP2304 is CCTCC NO:M 20241609, and the preservation number of ECP2307 is CCTCC NO:M 20241610.

[0008] Preferably, the pathogenic Escherichia coli comprises at least one of the following: MQ220627, MQ1 and YS220605;

[0009] Among them, the preservation number of MQ220627 is CCTCC NO:M 20241664, the preservation number of MQ1 is CCTCC NO:M20241665, and the preservation number of YS220605 is CCTCC NO:M 20241666.

[0010] The present invention provides a group of phage compositions for treating pathogenic Escherichia coli infection, comprising at least two of the following phages: ECP2301, ECP2304 and ECP2307;

[0011] Among them, the preservation number of ECP2301 is CCTCC NO:M 20241608, the preservation number of ECP2304 is CCTCC NO:M 20241609, and the preservation number of ECP2307 is CCTCC NO:M 20241610.

[0012] Preferably, the pathogenic Escherichia coli comprises at least one of the following: MQ220627, XMCS2207-5, MQ1 and YS220605;

[0013] Among them, the preservation number of MQ220627 is CCTCC NO:M 20241664, the preservation number of MQ1 is CCTCC NO:M20241665, and the preservation number of YS220605 is CCTCC NO:M 20241666.

[0014] The present invention provides the use of the bacteriophage or the bacteriophage composition in preparing a drug for inhibiting Escherichia coli infection in vitro.

[0015] The present invention also provides the use of the bacteriophage or the bacteriophage composition as a food pathogenic Escherichia coli remover.

[0016] Preferably, the food comprises dairy products or meat products.

[0017] The present invention provides a method for preparing the above-mentioned bacteriophage composition, comprising the following steps: (1) culturing bacteriophages ECP2301, ECP2304 and ECP2307 in Escherichia coli culture fluid respectively to obtain culture fluid;

[0018] (2) After centrifuging the culture solution of step (1), the supernatant containing the phages was diluted at different gradients, each dilution was mixed with the Escherichia coli culture solution and incubated, and then inverted into double-layer plates for incubation, and the plaques were counted to calculate the titers of the three phage strains;

[0019] (3) Adjust the titer of the three phage strains to (1.0±0.5)×10 9 PFU / mL, and the diluted phage solution is mixed to obtain the phage composition.

[0020] Preferably, the mixing ratio of the diluted phage solution in step (3) is 1:1:1.

[0021] The present invention also provides a method for removing pathogenic Escherichia coli from food, comprising the following steps: mixing a food sample with the above-mentioned bacteriophage composition or the bacteriophage composition prepared by the above-mentioned preparation method, reacting the mixture at 15-35°C for 2 hours, and obtaining food with pathogenic Escherichia coli removed.

[0022] Beneficial effects: The present invention provides a bacteriophage having a lytic effect on pathogenic Escherichia coli, wherein the bacteriophage includes ECP2301, ECP2304 and ECP2307, and the host bacteria of the bacteriophage composition are pathogenic Escherichia coli MQ220627, MQ1 and YS220605, respectively, and the bacteriophage composition has an important antibacterial effect on the host bacteria of pathogenic Escherichia coli. It has been verified by the examples that the five bacteriophages in the bacteriophage composition of the present invention have strong lytic properties on Escherichia coli MQ220627, MQ1 and YS220605, respectively, and after mixing the three bacteriophages, it is found that there is a synergistic effect between the bacteriophages, which has a more efficient inhibitory effect than a single bacteriophage, and can be used as a pathogenic Escherichia coli remover for milk and meat, and has good effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Circle maps of the whole genomes of phages ECP2301, ECP2304, and ECP2307;

[0024] Figure 2 This is a graph showing the results of a temperature sensitivity test of bacteriophage;

[0025] Figure 3 is the one-step growth curve of the phage;

[0026] Figure 4 is the in vitro inhibition curve of bacteriophage;

[0027] Figure 5 This is the result of the pH tolerance experiment of bacteriophage;

[0028] Figure 6 Figure 2 is the result of MOI determination;

[0029] Figure 7 The result of the host bacterium Escherichia coli, in the figure A: Colony morphology of Escherichia coli on eosin-methylene blue plate; B: Morphology under Gram staining microscope; C: Genetic evolution tree of Escherichia coli 16S rDNA sequence;

[0030] Figure 8 Plaques formed by bacteriophages;

[0031] Fig. 9 The morphology of bacteriophages under transmission electron microscopy; A: bacteriophage ECP2301, B: bacteriophage ECP2304, C: bacteriophage ECP2307;

[0032] Fig.10 The effect of phage preparation on the removal of E. coli on the surface of meat samples;

[0033] Fig.11 This is the effect of phage preparation on the removal of Escherichia coli in milk samples.

[0034] Biological deposit information

[0035] Escherichia coli YS220605, deposited on July 22, 2024 in China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with the deposit number CCTCC NO: M20241666;

[0036] Escherichia coli MQ1, deposited on July 22, 2024 in China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with the deposit number CCTCC NO: M 20241665;

[0037] Escherichia coli YS220627, deposited on July 22, 2024 in China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with the deposit number CCTCC NO: M20241664;

[0038] Bacteriophage ECP2307 was deposited in China Center for Type Culture Collection (CCTCC) on July 22, 2024, with the deposit address at Wuhan University, Wuhan, China, and the deposit number is CCTCC NO: M 20241610;

[0039] Bacteriophage ECP2304 was deposited in China Center for Type Culture Collection (CCTCC) on July 22, 2024, with the deposit address at Wuhan University, Wuhan, China, and the deposit number is CCTCC NO: M 20241609;

[0040] Bacteriophage ECP2301 was deposited in the China Center for Type Culture Collection (CCTCC) on July 22, 2024, with the deposit address being Wuhan University, Wuhan, China, and the deposit number being CCTCC NO: M 20241608. DETAILED DESCRIPTION

[0041] The present invention provides a bacteriophage having a lytic effect on pathogenic Escherichia coli, wherein the bacteriophage comprises at least one of the following: ECP2301, ECP2304 and ECP2307;

[0042] Among them, the preservation number of ECP2301 is CCTCC NO:M 20241608, the preservation number of ECP2304 is CCTCC NO:M 20241609, and the preservation number of ECP2307 is CCTCC NO:M 20241610.

[0043] The bacteriophage ECP2307 of the present invention is preferably isolated from sewage from a cattle farm in Yushu Prefecture, Qinghai Province, and the bacteriophages ECP2301 and ECP2304 are isolated from sewage from a cattle farm in Maqin County, Qinghai Province.

[0044] The pathogenic Escherichia coli of the present invention preferably includes at least one of the following: MQ220627, MQ1 and YS220605; wherein the deposit number of MQ220627 is CCTCC NO: M 20241664, the deposit number of MQ1 is CCTCC NO: M20241665, and the deposit number of YS220605 is CCTCC NO: M20241666. The pathogenic Escherichia coli of the present invention is preferably isolated from diarrhea yaks in some areas of Qinghai.

[0045] The host bacteria of the bacteriophages ECP2301, ECP2304 and ECP2307 of the present invention are pathogenic Escherichia coli MQ220627, MQ1 and YS220605, respectively, and they all have antibacterial effects on the host bacteria, showing strong lytic properties; after mixing the three bacteriophages, it was found that there was a synergistic effect between the phages, which had a more efficient inhibitory effect than a single phage.

[0046] The present invention provides a group of phage compositions for treating pathogenic Escherichia coli infection, comprising at least two of the following phages: ECP2301, ECP2304 and ECP2307;

[0047] Among them, the preservation number of ECP2301 is CCTCC NO:M 20241608, the preservation number of ECP2304 is CCTCC NO:M 20241609, and the preservation number of ECP2307 is CCTCC NO:M 20241610.

[0048] The bacteriophage and pathogenic Escherichia coli of the present invention are preferably the same as those described above and will not be described in detail herein.

[0049] The present invention provides the use of the bacteriophage or the bacteriophage composition in preparing a drug for inhibiting Escherichia coli infection in vitro.

[0050] The present invention utilizes a method of co-culturing pathogenic Escherichia coli and the phage composition to identify the in vitro inhibitory effect of the phage composition on Escherichia coli. The results show that the OD of each group of Escherichia coli liquid without the phage composition is 600 The average value increased over time and reached 0.71 at 9h. 600 The average value decreased over time and reached 0.21 at 9h ( Figure 4 ).

[0051] The present invention also provides the use of the bacteriophage or the bacteriophage composition as a food pathogenic Escherichia coli remover.

[0052] The food of the present invention preferably comprises dairy products or meat products.

[0053] The present invention provides a method for preparing the above-mentioned bacteriophage composition, comprising the following steps: (1) culturing bacteriophages ECP2301, ECP2304 and ECP2307 in Escherichia coli culture fluid respectively to obtain culture fluid;

[0054] (2) After centrifuging the culture solution of step (1), the supernatant containing the phages was diluted at different gradients, each dilution was mixed with the Escherichia coli culture solution and incubated, and then inverted into double-layer plates for incubation, and the plaques were counted to calculate the titers of the three phage strains;

[0055] (3) Adjust the titer of the three phage strains to (1.0±0.5)×10 9 PFU / mL, and the diluted phage solution is mixed to obtain the phage composition.

[0056] In the present embodiment, preferably 500 μL of purified phage is added to 50 mL of Escherichia coli culture solution (OD 600 =0.6) and then cultured at 37°C for 12 h; (2) The next day, centrifuged at 4°C and 8000 r / min for 15 min, and 100 μL of the supernatant containing phages was diluted to 10 -2 ,10 -4 ,10 -6 ,10 -8 ,10 -10 There are 5 gradients in total. Take 100 μL of phage diluted to each gradient and mix with 100 μL of E. coli solution (OD 600 =1.2) Mix and incubate for 10 min, pour into double-layer plates and culture at 37°C overnight. The next day, count the number of plaques and calculate the titers of the three phage strains (three replicates per group); (3) Dilute the titers of the three phage strains to (1.0±0.5)×10 9 PFU / mL, take an appropriate amount of diluted phage solution and mix them in a ratio of 1:1:1 to obtain an E. coli phage cocktail.

[0057] The present invention provides a method for removing pathogenic Escherichia coli from food, comprising the following steps: mixing a food sample with the above-mentioned bacteriophage composition or the bacteriophage composition prepared by the above-mentioned preparation method, and reacting the mixture for 2 hours at room temperature to obtain food with pathogenic Escherichia coli removed.

[0058] In the present invention, if the sample is liquid, 1 mL of the above phage cocktail is added to every 100 mL of the sample to be tested; if the sample is solid, the above phage cocktail is sprayed on the surface of the sample to be tested and allowed to act for 2 hours at room temperature to eliminate the pathogenic Escherichia coli in the sample to be tested. The room temperature referred to in the present invention refers to 15 to 35°C.

[0059] To further illustrate the present invention, the phage composition for treating pathogenic Escherichia coli infection, its preparation method and application provided by the present invention are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.

[0060] In the present invention, the abbreviations used are: MOI (multiplicity of infection): multiplicity of infection, indicating the ratio of the number of viruses to the number of cells during infection. PFU (plaque forming unit): plaque (phage class) forming unit. PFU / ml (Plaque Forming Unit per mL): infectivity titer, expressed as the number of plaques formed by a unit volume of virus. The burst volume (PFU / cell) is expressed as the ratio of the phage titer (PFU / ml) at the end of the burst to the host bacteria concentration (cell / ml) at the beginning of the lysis. ORF: open reading frame.

[0061] Example 1

[0062] 1. Isolation of bacteriophage

[0063] Pour the collected sewage into a conical flask, add SM buffer solution of one-fourth of the amount of sewage, and shake at 60rpm for 48h at room temperature. Centrifuge the above liquid at 10000rpm for 10min to take the supernatant, centrifuge 3-4 times, and filter the supernatant with a 0.45μm microfilter. Obtain the stock solution containing bacteriophages. Take 5ml 2×LB liquid culture medium, add 5ml stock solution and 200μL Escherichia coli liquid, and culture at 180rpm and 37℃ for 18h. Filter the co-culture liquid with a 0.22μm microfilter for use, take 200μL of the filtrate and 200μL of Escherichia coli liquid 1:1, incubate at 37℃ for 10min, add 10ml 0.5% LB semi-solid to the mixture, and pour it on the solidified LB culture medium to make a double-layer plate. Culture in a 37℃ constant temperature incubator for 18h, and observe the appearance of clear-edged and transparent plaques on the double-layer plate.

[0064] 2. Purification of phage

[0065] Pick a single plaque with large diameter and uniform growth and inoculate it into 1 ml SM buffer. Place it at 4℃ for 18 hours. Dilute the filtrate 10 times and take 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 100 μL of the filtrate of each concentration and 100 μL of E. coli liquid were mixed, 10 ml of LB semi-solid medium was added, and poured onto the solidified LB medium to make a double-layer plate, and cultured at 37°C for 18 hours. Purify 3 to 5 times according to the above method until clear and transparent plaques of uniform size appear on the plate, and the purification is complete.

[0066] Three phage strains were isolated and purified, using E. coli strains MQ220627, MQ1 and YS220605 as hosts, and named ECP2301, ECP2304 and ECP2307. After purification, they all showed clear and bright plaques of uniform size on the plate ( Figure 8 ); Genome sequencing results such as Figure 1 shown.

[0067] Table 1 Results of whole genome analysis of bacteriophages

[0068]

[0069] 3. Phage titer determination

[0070] Dilute the phage stock solution 10 times. Take a sterile test tube and add LB semi-solid culture medium, mix 100μL of E. coli culture and 100μL of phage dilutions of different concentrations at a ratio of 1:1, add 10mL of 0.5% semi-solid LB, and immediately pour into the solidified agar medium to make a double-layer plate, culture at 37℃ for 12-16h, select the plate with clear and transparent plaques to count and calculate its titer. Phage titer (PFU / mL) = average PFU / mL number × dilution factor × 10.

[0071] The average titers of the three phage strains measured by plate counting were: ECP2301 was 9.4×10 11 PFU / mL, ECP2304 is 3.8×10 11 PFU / mL, ECP2307 is 9.8×10 11 PFU / mL.

[0072] 4. Determination of host spectrum of bacteriophage

[0073] Pick a single plaque with large diameter and uniform growth to inoculate 5ml LB liquid culture medium, and add 200μL Escherichia coli liquid, 180rpm, 37℃ for 18h. Filter the co-culture liquid with a 0.22μm microfilter for later use. Take 200μL Escherichia coli liquid and add 10ml LB semi-solid culture medium, pour it on the solidified LB culture medium to make a double-layer plate, after drying, draw 10μL phage suspension and drop it on the surface of the bacterial lawn, and drop an equal amount of physiological saline as a control. After the droplet is dry, culture it in a 37℃ incubator for 18h and observe the results. The host spectrum of the phage composition is also determined according to the above method.

[0074] The plaque scoring criteria were in accordance with Phageology: From Theory to Practice, i.e., “+4” represented complete lysis, “+3” represented complete lysis in the spot area but with a faint background, “+2” represented a large amount of turbidity in the spot area, and “+1” represented the presence of individual phages.

[0075] The host spectrum determination of the three phages and the combination showed that ECP2301, ECP2304 and ECP2307 had different degrees of lysis ability against 34, 38 and 31 strains of Escherichia coli, respectively, and the phage combination had different degrees of lysis ability against 58 strains of Escherichia coli.

[0076] Table 2 Host spectrum of 3 phage strains and their combinations

[0077]

[0078]

[0079]

[0080] 5. Morphological observation of bacteriophage

[0081] Pipette 10 μL of phage suspension onto a copper grid and allow to settle for 10 min. Remove excess liquid with filter paper and then drop 10 μL of phosphotungstic acid (PTA) for staining for 5 to 10 min. Dry naturally and observe the phage morphology under a transmission electron microscope (TEM).

[0082] The head of phage ECP2301 is about 55.0nm long and the tail is about 20.0nm long; the head of phage ECP2304 is about 80.0nm long and the tail is about 87.0nm long; the head of phage ECP2307 is about 76.0nm long and the tail is about 116.0nm long ( Fig. 9 ).

[0083] 6. Determination of the optimal phage infection multiplicity (MOI)

[0084] Pick a single colony of the host E. coli and inoculate it into 5 mL of LB liquid medium for overnight culture. Determine the number of E. coli by plate count method, adjust the concentration of E. coli, and mix it with an equal volume of 100 μL of phage to make the phage infection multiplicity MOI = 10 -5 , 10 -4 , 10 -3 , 10 -2 , 10 -1 , 1, 10, 10 2 , 10 3 , 10 4 and 10 5 Add to 10 mL LB liquid. Gently shake at 37°C for 5 h, centrifuge at 8000 rpm for 10 min, filter, and dilute the filtrate to 10 12 , determine the phage titer, and the MOI with the highest titer is the optimal MOI.

[0085] The results are as follows Figure 6 As shown, the optimal MOI of phage ECP2301 is 0.0001, and the optimal MOI of phage ECP2304 and ECP2307 is 0.01.

[0086] 7. Isolation, screening and purification of pathogenic Escherichia coli

[0087] A small amount of aseptically collected diseased sample was inoculated into 10 mL of LB liquid culture medium and cultured at 37°C, 180 r / min overnight. The next day, the culture solution was streaked on an eosin-methylene blue plate and cultured at 37°C for 18-24 h. The next day, a purple-black single colony with a metallic luster was selected and purified on the plate for 2-3 times. The purified single colony was inoculated into LB liquid culture medium and cultured at 37°C, 180 r / min overnight. The next day, the bacterial solution was examined by Gram staining, and the bacterial genome was extracted. PCR amplification and sequencing were performed using 16SrDNA universal primers. The sequencing results were compared at NCBI, and a genetic evolutionary tree was made.

[0088] The results showed that the three isolated strains were purple-black with metallic luster and smooth and neat-edged colonies on eosin-methylene blue plates. They were red, non-spore-forming, blunt-ended, scattered or paired straight rods under staining microscopy. 16S rDNA sequence alignment and genetic evolutionary tree showed that the three strains were Escherichia coli ( Figure 7 ).

[0089] 8. Determination of one-step growth curve

[0090] Escherichia coli MQ220627, XMCS2207-5, MQ1, YS220605, and MQ2206-3 were used as host bacteria, respectively. The host bacteria were cultured overnight and the bacterial concentration was adjusted to 1.00×10 11 CFU / mL; Take 10mL LB liquid medium and add 1.00×10 8 PFU / mL phage solution and 1.00×10 8 100 μL of CFU / mL bacterial solution was gently shaken at 37°C. 500 μL of culture was taken at 0 min, 20 min, 40 min, 60 min, 80 min, 100 min, 120 min, 3 h, 4 h, 5 h, and 6 h, and filtered with a 0.22 μm microfilter to determine the phage titer. A one-step growth curve was drawn to obtain the incubation period, outbreak period, and lysis amount of the phage. Lysis amount = phage titer at the end of the outbreak / host bacteria concentration at the beginning of infection.

[0091] The results are as follows Figure 3 As shown, the incubation period of the three phage strains was 40 min; the outbreak period was 60 min, 140 min and 200 min respectively; and the lysis amount was 680 PFU / cell, 680 PFU / cell and 1450 PFU / cell respectively.

[0092] 9. Temperature sensitivity of bacteriophages

[0093] Take 600 μL of phage liquid and treat it at 20℃, 30℃, 40℃, 50℃, 60℃, 70℃ and 80℃ for 30min and 60min respectively, mix 100 μL of Escherichia coli liquid and 100 μL of phage dilution treated at different temperatures in a ratio of 1:1, add 10mL of 0.5% semi-solid LB, immediately pour into solidified agar medium to make a double-layer plate, culture at 37℃ for 12-16h, and then determine the titer of the phage.

[0094] The results are as follows Figure 2 As shown, the titer of phage ECP2301 did not change significantly under the conditions of 20-70°C; the titer of ECP2304 and ECP2307 did not change significantly under the conditions of 20-60°C; but as the temperature gradually increased, the titers of the three phages dropped sharply and were completely inactivated at 80°C.

[0095] 10. pH stability of bacteriophage

[0096] Use 0.1 mol / L HCl and NaOH solution to adjust the pH of sterile deionized water to 2.0-13.0, and take a titer of about 1.00×10 8 100 μL of PFU / mL phage solution was placed in a sterile EP tube, and 900 μL of deionized water of different pH values ​​was added. After mixing, each pH value was diluted to 10 8 The supernatant was taken at a 1:1 ratio with the original host bacteria and the phage titer was determined by the double-layer agar plate method.

[0097] The results are as follows Figure 5 As shown, at pH 3.0-12.0, the titers of the three phages did not change significantly, but when the pH was >12 or <3, the phage activity decreased rapidly until it was completely inactivated, indicating that SP3 has a strong tolerance to acidic or alkaline environments, but will be quickly inactivated under strong acid or alkaline conditions.

[0098] 11. Preparation of phage composition

[0099] (1) Take 500 μL of purified phage and add it to 50 mL of E. coli culture medium (OD 600 =0.6) and then cultured at 37°C for 12 h; (2) the next day, centrifuged at 4°C and 8000 r / min for 15 min, and 100 μL of the supernatant containing phages was diluted to 10 -2 ,10 -4 ,10 -6 ,10 -8 ,10 -10 There are 5 gradients in total. Take 100 μL of phage diluted to each gradient and mix with 100 μL of E. coli solution (OD 600=1.2) Mix and incubate for 10 min, pour into double-layer plates and culture overnight at 37°C. The next day, count the plaques and calculate the titers of the three phage strains (three replicates per group); (3) Dilute and adjust the titers of the three phage strains to 1.0×10 9 PFU / mL, take an appropriate amount of diluted phage solution and mix them in a ratio of 1:1:1 to obtain an E. coli phage cocktail.

[0100] 12. In vitro antibacterial test of bacteriophage

[0101] 58 pathogenic E. coli strains were cultured overnight to an initial OD value between 0.2 and 0.4. 100 μL of E. coli and 100 μL of LB were added to the control group; 100 μL of E. coli and 100 μL of phage combination were added to the experimental group. The OD value of the bacterial solution was measured every hour for 9 hours. The average value was calculated and plotted.

[0102] The results are as follows Figure 4 As shown, the OD of each group of Escherichia coli culture without adding phage composition 600 The average value increased over time and reached 0.71 at 9h. 600 The average value decreased over time and reached 0.21 at 9h.

[0103] Table 358 Escherichia coli strain information

[0104]

[0105]

[0106] 13. Antibacterial test of bacteriophage preparations on meat products

[0107] Dilute the overnight cultured E. coli to 3.0 × 10 7 CFU / mL, the fresh beef samples were immersed in the E. coli dilution for 1 min, and then the samples were divided into a treated group and an untreated group. The treated group was surface sprayed with 1.0×10 9 The untreated group was sprayed with an equal amount of SM buffer and allowed to stand at room temperature. The two groups of meat samples were treated with a high-throughput tissue grinder at 0 h, 1 h, 2 h, and 3 h, and the E. coli load in the samples was determined by the plate gradient dilution method, with 3 replicates in each group. Fig.10 As shown in Figure 2, the initial average bacterial load of E. coli in the two groups of samples was 8.5×10 7CFU / mL. The bacterial load of E. coli in meat samples treated with phage preparations continued to decrease with time. At 3 h, the average bacterial load of the treated group was <100 CFU / mL, while the average bacterial load of the untreated group was >4.5×10 7 CFU / mL.

[0108] 14. Antibacterial test of bacteriophage preparations on dairy products

[0109] Dilute the overnight cultured E. coli to 3.0 × 10 7 CFU / mL, 1 mL of diluted E. coli solution was added to 100 mL of fresh milk, and the milk samples were divided into a treated group and an untreated group. The treated group was added with a titer of 1.0×10 10 The untreated group was sprayed with an equal amount of SM buffer solution and allowed to stand at room temperature. Appropriate amounts of milk samples were taken at 0 h, 1 h, 2 h, and 3 h, and the E. coli load in the samples was determined by the plate gradient dilution method. Each group was repeated 3 times. Fig.11 As shown in Figure 2, the initial average bacterial load of E. coli in the two groups of samples was 3.0×10 5 CFU / mL. The bacterial load of E. coli in milk samples treated with phage preparations continued to decrease with time. At 3 h, the average bacterial load of the treated group was 240 CFU / mL, and the average bacterial load of the untreated group was 2.0×10 8 CFU / mL.

[0110] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Bacteriophage that has a lytic effect on pathogenic Escherichia coli. It is characterized in that The bacteriophage comprises at least one of the following: ECP2301, ECP2304 and ECP2307; Among them, the preservation number of ECP2301 is CCTCC NO:M 20241608, the preservation number of ECP2304 is CCTCC NO:M20241609, and the preservation number of ECP2307 is CCTCC NO:M 20241610.

2. The bacteriophage according to claim 1, It is characterized in that The pathogenic Escherichia coli comprises at least one of the following: MQ220627, MQ1 and YS220605; Among them, the preservation number of MQ220627 is CCTCC NO:M 20241664, the preservation number of MQ1 is CCTCC NO:M20241665, and the preservation number of YS220605 is CCTCC NO:M 20241666.

3. A group of bacteriophage compositions for treating pathogenic Escherichia coli infection, It is characterized in that The invention relates to at least two of the following bacteriophages: ECP2301, ECP2304 and ECP2307; Among them, the preservation number of ECP2301 is CCTCC NO:M 20241608, the preservation number of ECP2304 is CCTCC NO:M20241609, and the preservation number of ECP2307 is CCTCC NO:M 20241610.

4. The phage composition according to claim 3, It is characterized in that The pathogenic Escherichia coli includes at least one of the following: MQ220627, MQ1 and YS220605; Among them, the preservation number of MQ220627 is CCTCC NO:M 20241664, the preservation number of MQ1 is CCTCC NO:M20241665, and the preservation number of YS220605 is CCTCC NO:M 20241666.

5. Use of the bacteriophage according to claim 1 or 2 or the bacteriophage composition according to claim 3 or 4 in the preparation of a drug for inhibiting Escherichia coli infection in vitro.

6. Use of the bacteriophage according to claim 1 or 2 or the bacteriophage composition according to claim 3 or 4 as a food pathogenic Escherichia coli remover.

7. The use according to claim 6, It is characterized in that The food includes dairy products or meat products.

8. A method for preparing the phage composition according to claim 3 or 4, It is characterized in that The method comprises the following steps: (1) culturing bacteriophages ECP2301, ECP2304 and ECP2307 in Escherichia coli culture medium respectively to obtain culture medium; (2) After centrifuging the culture solution of step (1), the supernatant containing the phages was diluted at different gradients, each dilution was mixed with the Escherichia coli culture solution and incubated, and then inverted into double-layer plates for incubation, and the plaques were counted to calculate the titers of the three phage strains; (3) Adjust the titer of the three phage strains to (1.0±0.5)×10 9 PFU / mL, and the diluted phage solution is mixed to obtain the phage composition.

9. The preparation method according to claim 8, It is characterized in that The mixing ratio of the diluted phage liquid in step (3) is 1:1:

1.

10. A method for removing pathogenic Escherichia coli from food, It is characterized in that The method comprises the following steps: mixing a food sample with the bacteriophage composition described in claim 3 or 4 or the bacteriophage composition prepared by the preparation method described in claim 8 or 9, and reacting the mixture for 2 hours at 15 to 35° C. to obtain food free of pathogenic Escherichia coli.

Citation Information

Patent Citations

  • Coliphage and application thereof, as well as bactericidal composition and application of bactericidal composition

    CN111187757A

  • Escherichia coli bacteriophage, and bacteriophage composition and application thereof

    CN117603918A

  • Bacteriophage strains, compositions and related methods

    WO2016003307A1